Barclays Rates 10x Genomics (TXG) buy, $40 Price Target
Barclays analyst Luke Sergott maintains a buy rating on 10x Genomics, setting a $40 price target, a 9.42% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Barclays rated 10x Genomics, Inc. ($TXG) "buy" with a $40 price target on June 24, 2026.
Since the rating, $TXG is up 12.9% after 1 week, up 33.7% after 1 month and up 101.9% to date (from the $34.60 close on Jun 24, 2026).
TXG
10x Genomics, Inc.
Key Points
- Barclays reiterated its buy rating for 10x Genomics, Inc. (TXG) with a price target of $40, as announced on June 24, 2026.
- Barclays's $40 price target implies 9.42% upside from 10x Genomics, Inc.'s ($TXG) current $36.55 share price.
- Shares of TXG traded at $33.98 on Wednesday, with a market cap of $4.18 billion and a forward P/E of 164.7.
- FMR LLC increased its stake in 10x Genomics by 48.9%, holding 17.74 million shares valued at $376.64 million.
Get $TXG trade alerts by text
We text you when insiders, Congress or big funds trade $TXG. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated 10x Genomics, Inc. alert may contain errors. Disclosures
Barclays has reiterated its buy rating on 10x Genomics, Inc. (NasdaqGS: TXG), setting a price target of $40. Analyst Luke Sergott shared this update on June 24, 2026, suggesting continued confidence in the company's prospects.
Barclays vs. the S&P 500
Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in 10x Genomics
FMR LLC grew its holdings by 5.82 million shares, ending with 17.74 million shares worth about $376.64 million. ARK Investment Management LLC reduced its position by 950,052 shares, now holding 11.72 million shares valued at approximately $248.76 million, a decrease of 7.5%. BlackRock, Inc. added 65,451 shares, bringing its total to about 10.08 million shares valued at $213.99 million, a modest increase of 0.7%. Vanguard Portfolio Management LLC opened a new position with 6.91 million shares worth $146.76 million.
10x Genomics, Inc. Stock Down 52.3%
Shares of 10x Genomics traded near $33.98 on Wednesday. The company has a market cap of $4.18 billion, a forward P/E ratio of 164.7, and a beta of 2.114. The stock's 52-week range is between $10.48 and $36.59, with a 50-day moving average of $25.33 and a 200-day moving average of $19.10. The company maintains a strong liquidity position with a current ratio of 5.90 and a quick ratio of 5.25, while its debt-to-equity ratio stands at 10.0.
$TXG price target
10x Genomics, Inc. daily closes and this analyst's $40 target. Not advice.
Recent Earnings
10x Genomics reported revenue of $638.78 million, experiencing a slight decline in revenue growth by 2.6%. The company is not yet profitable, with a net margin of -3.55% and a return on equity of -2.98%. The next earnings report is scheduled for August 6, 2026.
Analysts Set New Price Targets
On June 24, 2026, Barclays maintained a buy rating on 10x Genomics with a $40 price target. Other analysts have varied views: Morgan Stanley and JP Morgan both maintained hold ratings with targets of $22 and $20, respectively, on May 12, 2026. Canaccord Genuity reiterated a buy rating with a $32 target on April 20, 2026. The consensus rating is a buy, with a mean target price of $26.85 based on 13 analyst opinions.
About 10x Genomics, Inc.
10x Genomics, Inc. is a healthcare company based in Pleasanton, California. It specializes in developing and selling tools for analyzing biological systems. The company offers platforms like Chromium and Visium, which are used in single-cell and spatial analysis. 10x Genomics serves academic, government, and biopharmaceutical institutions and is led by CEO Dr. Serge Saxonov.
Bottom Line
Barclays' reiteration of its buy rating on 10x Genomics with a $40 target reflects optimism about the company's future. Institutional interest remains strong, with significant activity among major funds. Investors will be watching the upcoming earnings report for further insights into the company's performance.
Related Filing Alerts
Source: Barclays's rating change on $TXG (Jun 24, 2026). Written by software, not financial advice. How we make alerts